Methods	Allocation: randomised. Blindness: double. Duration: 8 weeks.
Participants	Diagnosis: (DSM-IV) schizophrenia, treatment resistance to two previous antipsychotic medications, BPRS score of 27 or more. N=23. Age: 18 years or more (mean clozapine=38.3 years, mean olanzapine=34.1 years) (of completer population). Gender: 16 M, 7 F. Setting: inpatient. History: duration ill not reported, age at onset not reported
Interventions	Clozapine: flexible dose. Allowed dose range: 300-400 mg/day. Mean dose: 325.4 mg/day. N=12. Olanzapine: flexible dose. Allowed dose range: 15-20 mg/day. Mean dose: 18.3 mg/day. N=11
Outcomes	Leaving the study early: any reason, adverse events, inefficacy. Mental state: PANSS total score, BPRS total score, PANSS positive and negative sub-score. Adverse effects: at least one adverse effect, extrapyramidal side effects (SAS) Unable to use: AIMS (no useable data)
Notes
Risk of bias
Item	Authors’ judgement	Description
Adequate sequence generation?	Unclear	Quote: “Before randomisation..” Comment: Information incomplete.
Allocation concealment?	No	Probably not done.
Blinding? All outcomes	Yes	Quote:“ A double blind, parallel study.” Comment: Probably done. The success of blinding was not evaluated
Incomplete outcome data addressed? All outcomes	No	6/12 missing from clozapine and 2/11 missing from olanzapine ITT not performed.
Free of selective reporting?	Unclear	No information about form to assess the adverse events.
Free of other bias?	Unclear	Quote: “Study was partially supported by Eli-Lilly”